University of Chicago Medicine

Comprehensive Cancer Center

Chicago, IL

Website

(888) 828-2206 Refer Patient

Filters

Help Me Find Trials

Sort by

Not currently accepting

CARTITUDE-2

Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma

Learn more

CAR T Cell
BCMA
Phase 2

Not yet accepting

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma

Learn more

CAR T Cell
GPRC5D
Phase 2

Get personalized results in 60 seconds

All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.

Help me find trials

Not currently accepting

EXCALIBER-Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma

Learn more

CELMoD
Randomization
Phase 3

Accepting patients

MonumenTAL-1

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Learn more

Bispecific Antibody
GPRC5D
Phase 2

Accepting patients

Belantamab Mafodotin

Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma

Learn more

Antibody Drug Conjugate (ADC)
BCMA
Quadruplet Therapy
Phase 2

Not yet accepting

Impact of Non-Profit on Patient Outcomes & Care

The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial

Learn more

Randomization
Observational Trial

Not yet accepting

Radiation to Treat Multiple Myeloma

An i3+3 Phase I Hypofractionation Trial for Multiple Myeloma

Learn more

Radiation
Phase 1

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Learn more